Home
Subscription
January 2025 issue
BACK ISSUES
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
|
2015 Issues
December 2015 Issue
• Feature: How Shall We Live?
• "Support Independents"
• Appreciation
• Indexes for Volume 6, 2011 through Volume 9, 2014
• Index for Volume 10, 2015
November 2015 Issue
• Feature: Medications that Must Be Available without a Prescription from a Pharmacist
• New Drug Review: Brexpiprazole (Rexulti – Otsuka)
October 2015 Issue
• Feature: The FTC should just say NO! to CVS acquiring Target pharmacies and to Walgreens acquiring Rite Aid!
• New Drug Review: Sacubitril/valsartan (Entresto – Novartis)
September 2015 Issue
• Feature: Daraprim – The Ultimate Drug Pricing Outrage?
• New Drug Review: Suvorexant (Belsomra – Merck)
August 2015 Issue
• Feature: CVS Recommendations about the Cholesterol Guidelines are Not Credible When Its Pharmacists Do Not Have Enough Staff and Time to Practice Optimally
• New Therapeutic Agents Marketed in the United States in 2014
July 2015 Issue
• Feature: Time Out!*
• New Drug Review: Edoxaban tosylate monohydrate (Savaysa – Daiichi-Sankyo)
March 2015 Issue
• Feature: PHARMACY'S VISION FOR 2015 [2004-2014 Rest in Peace]
• New Drug Review: Vorapaxar sulfate (Zontivity – Merck)
February 2015 Issue
• Feature: Drug Shortages and High-Priced Generics – Pharmacy Should Establish Our Own Generics Pharmaceutical Company!
• New Drug Review: Olodaterol hydrochloride (Striverdi Respimat – Boehringer Ingelheim)
January 2015 Issue
• Feature: Express Scripts Made the Wrong Formulary Decision that is a Disservice to its Customers
• New Drug Review: Ledipasvir/sofosbuvir (Harvoni – Gilead Sciences)
• New Drug Review: Ombitasvir, paritaprevir, ritonavir, dasabuvir sodium monohydrate (Viekira Pak – AbbVie)
| |
